US EditionHeidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 – Optimum Strategic CommunicationsLink to: Sector updates in MarchLink to: Hot topic: What if weight loss drugs are just the first longevity game-changers?Scro
Summary by Optimum Strategic Communications
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 – Optimum Strategic CommunicationsLink to: Sector updates in MarchLink to: Hot topic: What if weight loss drugs are just the first longevity game-changers?Scro
Ladenburg, Germany, 26 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it will be presenting its latest ADC research results and advancement for its Exatecan-based ADC technology platform at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois, USA, […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
